750 related articles for article (PubMed ID: 16982227)
1. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
Jick SS; Jick H
Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
[TBL] [Abstract][Full Text] [Related]
2. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
4. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction.
Jick SS; Jick H
Pharmacotherapy; 2007 Feb; 27(2):218-20. PubMed ID: 17253912
[TBL] [Abstract][Full Text] [Related]
5. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Cole JA; Norman H; Doherty M; Walker AM
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
[TBL] [Abstract][Full Text] [Related]
7. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
8. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
9. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.
Hannaford PC; Kay CR
Br J Gen Pract; 1998 Oct; 48(435):1657-62. PubMed ID: 10071398
[TBL] [Abstract][Full Text] [Related]
10. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
11. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
12. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses.
Lindberg M; Foldemo A; Josefsson A; Wiréhn AB
Eur J Contracept Reprod Health Care; 2012 Apr; 17(2):106-18. PubMed ID: 22385398
[TBL] [Abstract][Full Text] [Related]
13. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
14. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
[TBL] [Abstract][Full Text] [Related]
15. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
16. [Contraceptive agents and risk of thrombosis].
Maurer-Major E; Keller PJ
Praxis (Bern 1994); 1997 Oct; 86(40):1543-8. PubMed ID: 9417570
[TBL] [Abstract][Full Text] [Related]
17. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
19. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
20. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
Tepper NK; Dragoman MV; Gaffield ME; Curtis KM
Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
